US2017009301A1PendingUtilityA1
Method for diagnosing hematological disorders
Assignee: UNIV FRANCOIS RABELAIS DE TOURSPriority: Dec 22, 2010Filed: Sep 28, 2016Published: Jan 12, 2017
Est. expiryDec 22, 2030(~4.4 yrs left)· nominal 20-yr term from priority
C12Q 2600/158C12Q 1/6883C12Q 2600/112C12Q 1/6886
31
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed is a method for the diagnosis, and/or the classification, of a hematological disorder, including the steps of: a). measuring, the expression level of at least the genes of a sub-group of 6 genes, b). comparing the expression level of each genes measured in step a)., with the expression level of the same genes in healthy control sample, and c). determining the status of the biological sample.
Claims
exact text as granted — not AI-modified1 . A composition comprising at least 12 oligonucleotides chosen among a library of 48 oligonucleotides comprising or consisting of the nucleic acid sequences SEQ ID NO: 25-72.
2 . The composition according to claim 1 , wherein said composition comprises at least the 12 oligonucleotides that comprise or consist of the nucleic acid sequences SEQ ID NO: 25-36.
3 . A kit comprising at least 12 oligonucleotides chosen among a group of 48 oligonucleotides comprising or consisting of the nucleic acid sequences SEQ ID NO: 25-72, said at least 12 oligonucleotides comprising or consisting of the nucleic acid sequences SEQ ID NO: 25-36.
4 . A method for diagnosis, and/or the classification, preferably in vitro, of an hematological disorder, in particular myeloid and/or lymphoid hematological disorder, preferably myeloid hematological disorder comprising, comprising measuring an expression level of a gene using the composition according to claim 1 .Join the waitlist — get patent alerts
Track US2017009301A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.